Phase 2 Single Arm, Open-Label Study of IMC-A12 in Asymptomatic, Chemotherapy-Naive Patients With Metastatic Androgen-Independent Prostate Cancer.
Phase of Trial: Phase II
Latest Information Update: 25 Jul 2018
At a glance
- Drugs Cixutumumab (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors Eli Lilly
- 10 Jun 2017 Biomarkers information updated
- 14 Feb 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Feb 2013 Planned End Date changed from 1 Jun 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.